Regarding the treatment for type 2 diabetes mellitus in the cohort of patients with CKD, it was possible to identify that the most commonly used drugs were metformin alone or associated with some other antidiabetic, followed by dipeptidyl peptidase-4 (DPP4) inhibitors (especially linagliptin and sitagliptin), some type of insulins (particularly long-acting and short-acting analogs), and sulfonylureas. This evidence concerns the gene DPP4 and chronic kidney disease.